Friday, July 31, 2026

AI-Designed Proteins: How KAIST’s Breakthrough Could Revolutionize Disease Diagnosis and Drug Development

KAIST's Professor Lee Kyu Ri has designed AI-based artificial proteins for specific compound recognition, enabling advanced biosensors.

North Korea’s Destroyer Capsize Highlights Structural Failures and Inexperience

North Korea's second destroyer may be a total loss after capsizing during launch, contradicting claims of minor damage.

GLE 350 4MATIC Rolls In With Mild Hybrid Tech and 258 HP

Mercedes-Benz launches GLE 350 4MATIC, an entry-level SUV trim featuring a 258 hp engine and luxury amenities, priced from $81,631.

Tag: pharmacokinetics

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

IVL3021 vs Wegovy: The Future of Long-Acting Obesity Treatments Revealed

Inventage Lab's IVL3021 shows promising long-term obesity treatment results, outperforming competitors with effective weight maintenance strategies.

Daewoong’s Enavogliflozin Shows Consistent Glucose-Lowering Effects Across Korean and Chinese Patients

Daewoong's diabetes drug Enblo shows similar effects in Korean and Chinese patients, supporting its global expansion and future approvals.

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp's YH35995 shows promising results for Gaucher disease in Phase 1 trial, demonstrating long-lasting efficacy and BBB penetration.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

Celltrion’s ‘Psoriasis’ Biosimilar Poised to Challenge Big Pharma with Phase 1 Data

The EADV conference in Paris showcased Celltrion's biosimilar CT-P55, confirming its equivalence to Cosentyx in safety and pharmacokinetics.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.